Skip to main content

Table 2 Changes in outcomes from baseline to time points of follow-up by ITT and PP analysis

From: Effects and long-term outcomes of endurance versus resistance training as an adjunct to standard medication in patients with stable COPD: a multicenter randomized trial

 

ITT population

PP population

Variables

Treatment

Time

Time

T3

T6

T12

T3

T6

T12

Primary outcomes

 ΔSGRQ

MT

-1.78 ± 0.30

-2.23 ± 0.25

-2.25 ± 0.42

-1.79 ± 0.25

-2.25 ± 0.34

-2.29 ± 0.30

MT + ET

-1.25 ± 0.27

-1.37 ± 0.41

-1.30 ± 0.55

-1.13 ± 0.20

-1.39 ± 0.34

-1.16 ± 0.54

MT + RT

-1.53 ± 0.31

-1.62 ± 0.34

-1.73 ± 0.40

-1.29 ± 0.28

-1.37 ± 0.44

-2.17 ± 0.48

MT

5.12 ± 2.01

6.05 ± 2.28

5.07 ± 2.74

5.05 ± 1.51

6.00 ± 2.07

4.99 ± 3.33

 Δ3MWD(m)

MT + ET

2.55 ± 1.61

13.28 ± 3.07*

20.53 ± 2.58* a

2.09 ± 1.49

13.23 ± 2.05*

22.78 ± 3.29* a

MT + RT

3.12 ± 1.15

11.79 ± 2.38

14.74 ± 3.02

2.60 ± 1.59

12.13 ± 2.19

15.12 ± 3.50

Secondary outcomes

 ΔCAT

MT

-0.95 ± 0.25

-1.81 ± 0.30

-2.57 ± 0.53#

-0.96 ± 0.20

-1.85 ± 0.28

-2.79 ± 0.40#

MT + ET

-0.72 ± 0.23

-1.64 ± 0.45

-1.96 ± 0.42

-0.78 ± 0.15

-1.56 ± 0.27

-2.07 ± 0.36#

MT + RT

-0.78 ± 0.25

-1.58 ± 0.29

-2.01 ± 0.37#

-0.81 ± 0.22

-1.64 ±0.34

-2.25 ± 0.52#

MT

-0.08 ± 0.05

-0.21 ± 0.09

-0.27 ± 0.08

-0.08 ± 0.03

-0.20 ± 0.08

-0.28 ± 0.10

 ΔmMRC

MT + ET

-0.18 ± 0.05

-0.39 ± 0.07

-0.51 ± 0.05#

-0.24 ± 0.06

-0.45 ± 0.08

-0.57 ± 0.09#

MT + RT

-0.20 ± 0.08

-0.22 ± 0.09

-0.24 ± 0.11

-0.22 ± 0.06

-0.25 ± 0.08

-0.28 ± 0.10

MT

0.04 ± 0.17

-0.15 ± 0.20

-0.13 ± 0.25

0.04 ± 0.23

-0.12 ± 0.26

-0.11 ± 0.32

 ΔHAD-A

MT + ET

-0.30 ± 0.18

-0.42 ± 0.21

-0.10 ± 0.15

-0.38 ± 0.21

-0.52 ± 0.23

0.05 ± 0.21

MT + RT

-0.16 ± 0.20

0.11 ± 0.16

0.35 ± 0.23

0.14 ± 0.23

0.20 ± 0.25

0.43 ± 0.31

MT

-0.22 ± 0.30

-0.37 ± 0.25

-0.40 ± 0.20

-0.23 ± 0.26

-0.40 ± 0.30

-0.41 ± 0.08

 ΔHAD-D

MT + ET

-0.92 ± 0.31

-1.26 ± 0.21

-1.55 ± 0.25* #

-0.90 ± 0.26

-1.24 ± 0.27

-1.60 ± 0.29* #

MT + RT

-0.45 ± 0.25

-0.70 ± 0.30

-0.98 ± 0.28

-0.49 ± 0.30

-0.70 ± 0.29

-1.01 ± 0.32

MT

0.015 ± 0.03

0.038 ± 0.03

0.042 ± 0.03

0.015 ± 0.02

0.039 ± 0.02

0.045 ± 0.03

 ΔFEV1(L)

MT + ET

0.021 ± 0.02

0.065 ± 0.03

0.171 ± 0.03*

0.020 ± 0.02

0.069 ± 0.02

0.176 ± 0.03*

MT + RT

0.025 ± 0.03

0.044 ± 0.02

0.090 ± 0.02

0.022 ± 0.02

0.043 ± 0.02

0.089 ± 0.03

MT

0.014 ± 0.02

0.024 ± 0.03

0.037 ± 0.01

0.015 ± 0.02

0.025 ± 0.02

0.037 ± 0.03

 ΔFVC(L)

MT + ET

0.020 ± 0.03

0.051 ± 0.02

0.158 ± 0.02*

0.019 ± 0.02

0.047 ± 0.02

0.169 ± 0.03*

MT + RT

0.022 ± 0.02

0.055 ± 0.03

0.145 ± 0.02*

0.020 ± 0.02

0.059 ± 0.02

0.152 ± 0.02*

  1. Δ, value changes between the baseline and different time points of follow-up
  2. T3 at the end of programs, T6 and T12 at 6 and 12-month follow-up, SGRQ St George’s Respiratory Questionnaire, 3MWD 3min walking distance, CAT COPD assessment test, mMRC Modified Medical Research Council, HADS Hospital Anxiety and Depression Scale (D = depression subscale; A = anxiety subscale), ITT Intention-to-treat, PP per-protocol
  3. Data are presented as mean ± SEM. #, the change in value exceeded the minimum clinically important difference (MCID) for the outcome
  4. *Different from the MT group: P < 0.05. aDifference between the exercise training groups: P < 0.05
Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us